Delivery Order SPE2DE24D0013-SPE2D625F3FSA
- Not listed
- The U.S. Defense Department's Medical Supply Chain division awarded a $19,375 firm fixed-price delivery order to Cepheid Inc. on September 8, 2025, with an ultimate completion date of September 15, 2025. This delivery order (XPRS4PLEX-10) represents a continuation of the federal government's ongoing procurement of molecular diagnostic solutions from the Sunnyvale, California-based manufacturer. The award carries no set-aside designation and is likely issued under one of Cepheid's existing...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a delivery order valued at $1,840 on August 11, 2025, by the Defense Department's Medical Supply Chain agency. This firm fixed-price contract, designated as XPRSTREPA-10, is set to conclude by August 18, 2025, and will be performed at Cepheid's Sunnyvale facility. The contract represents a discrete delivery order under Cepheid's existing federal contracting relationships, through which the...
- The U.S. Defense Medical Supply Chain awarded a $13.6K delivery order to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, on September 2, 2025, with completion targeted for September 9, 2025. This firm fixed-price delivery order (Contract No. 4569302261) procures diagnostic testing capabilities for COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The contract carries no set-aside designation and represents a continuation of...
- This delivery order, issued on July 28, 2025, awards Cepheid Inc. a firm fixed-price contract valued at $1,190.28 for molecular diagnostic solutions under a Defense Logistics Agency Medical Supply Chain program. The contract is set to be completed by August 11, 2025, with performance taking place at Cepheid's headquarters in Sunnyvale, California. The award reflects the company's established role as a key supplier of diagnostic systems and reagents to federal defense and healthcare agencies,...
- Cepheid, a leading manufacturer of molecular diagnostic solutions based in Sunnyvale, California, was awarded a delivery order valued at $2,471.70 by the Medical Supply Chain division of the Defense Department on August 7, 2025. This firm fixed-price delivery order, which carries no set-aside designation, is scheduled for ultimate completion by August 21, 2025, and will be performed at Cepheid's Sunnyvale facility. The contract award references XPRSARS-COV2-10, indicating the delivery order...
- The U.S. Defense Department's Medical Supply Chain organization awarded Cepheid Inc., a molecular diagnostics manufacturer based in Sunnyvale, California, a $4,108.25 firm fixed-price delivery order (Contract No. 4569031063) on August 7, 2025, with completion scheduled for August 14, 2025. This delivery order carries no set-aside designation and represents a procurement of diagnostic solutions from Cepheid's established product portfolio. The award leverages Cepheid's expertise in molecular...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a firm fixed-price delivery order valued at $6,390 on September 9, 2025, by the Defense Department's Medical Supply Chain office. The delivery order, designated XPRS4PLEX-10, has an ultimate completion date of September 16, 2025, and involves performance at Cepheid's Sunnyvale facility. This award carries no set-aside designation and represents a discrete procurement action under the company's...
- The U.S. Defense Department's Medical Supply Chain organization awarded a delivery order valued at $9,319 to Cepheid Inc., a molecular diagnostics manufacturer based in Sunnyvale, California, on September 1, 2025. This firm fixed-price delivery order, with an ultimate completion date of September 15, 2025, carries no set-aside designation and represents work to be performed at Cepheid's Sunnyvale facility. The delivery order is issued under one of Cepheid's existing Indefinite Delivery Vehicle...
- The U.S. Defense Department's Medical Supply Chain awarded a $4,815 delivery order to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, on August 7, 2025, with ultimate completion targeted for August 21, 2025. This firm fixed-price delivery order carries no set-aside designation and represents work to be performed at Cepheid's Sunnyvale facility. The award is likely associated with one of Cepheid's existing Indefinite Delivery Vehicle contracts with...
- The Defense Department's Medical Supply Chain awarded a $25,920 firm fixed-price delivery order to Cepheid Inc. on September 9, 2025, with an ultimate completion date of September 16, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic solutions from the Sunnyvale, California-based manufacturer, likely supporting testing capabilities for COVID-19, influenza, and respiratory syncytial virus (RSV) detection across federal healthcare systems. This award carries...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F3FSADelivery Order
This delivery order, awarded to Cepheid Inc. on September 11, 2025, represents a firm fixed-price contract valued at $1,155 with a completion date of September 18, 2025. The award was issued by the Medical Supply Chain division within the Department of Defense and will be performed at Cepheid's facility in Sunnyvale, California. No small business set-aside designation was applied to this contract. Cepheid, a leading manufacturer of molecular diagnostic solutions, specializes in GeneXpert diagnostic systems and associated test kits for detecting infectious diseases including COVID-19, influenza, and respiratory pathogens. This delivery order is likely issued under one of Cepheid's existing Indefinite Delivery Vehicle contracts with the Department of Veterans Affairs, which provide the framework for procuring molecular diagnostic testing systems and reagents on a firm fixed-price basis. Cepheid maintains substantial IDV vehicles with VA networks, including a single-award contract valued at approximately $32.8 million through 2030 and another valued at $2.5 million focused on PCR testing for laboratory microbiology. The company has established itself as a key supplier of diagnostic capabilities across multiple federal healthcare systems, including the Veterans Health Administration, Defense Logistics Agency, and Indian Health Service, delivering critical testing solutions to support patient care and disease surveillance initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/11/25 |